Switzerland-based pharmaceutical company, Novartis AG ( NVS ) recently announced phase III data on its pipeline candidate, RLX030 (serelaxin), from the six month, RELAX-AHF study. The
Read More:
Phase III Data on Novartis’ RLX030 – Analyst Blog
Switzerland-based pharmaceutical company, Novartis AG ( NVS ) recently announced phase III data on its pipeline candidate, RLX030 (serelaxin), from the six month, RELAX-AHF study. The
Read More:
Phase III Data on Novartis’ RLX030 – Analyst Blog